Calidi Biotherapeutics, Inc. (CLDI)

USD 1.44

(-16.76%)

EBITDA Summary of Calidi Biotherapeutics, Inc.

  • Calidi Biotherapeutics, Inc.'s latest annual EBITDA in 2023 was -28.6 Million USD , down -21.29% from previous year.
  • Calidi Biotherapeutics, Inc.'s latest quarterly EBITDA in 2024 Q2 was -5.39 Million USD , up 22.54% from previous quarter.
  • Calidi Biotherapeutics, Inc. reported an annual EBITDA of -24.99 Million USD in 2022, down -1183.49% from previous year.
  • Calidi Biotherapeutics, Inc. reported an annual EBITDA of -9.45 Million USD in 2021, up 73.22% from previous year.
  • Calidi Biotherapeutics, Inc. reported a quarterly EBITDA of -6.37 Million USD for 2024 Q1, up 13.76% from previous quarter.
  • Calidi Biotherapeutics, Inc. reported a quarterly EBITDA of -9.45 Million USD for 2023 Q4, down -32.79% from previous quarter.

Annual EBITDA Chart of Calidi Biotherapeutics, Inc. (2023 - 2020)

Historical Annual EBITDA of Calidi Biotherapeutics, Inc. (2023 - 2020)

Year EBITDA EBITDA Growth
2023 -28.6 Million USD -21.29%
2022 -24.99 Million USD -1183.49%
2021 -9.45 Million USD 73.22%
2020 -6.65 Million USD 0.0%

Peer EBITDA Comparison of Calidi Biotherapeutics, Inc.

Name EBITDA EBITDA Difference
AIM ImmunoTech Inc. -31.67 Million USD 9.717%
Ampio Pharmaceuticals, Inc. - USD Infinity%
Armata Pharmaceuticals, Inc. -39.91 Million USD 28.353%
Actinium Pharmaceuticals, Inc. -51.13 Million USD 44.064%
Azitra, Inc. -10.67 Million USD -167.961%
Can-Fite BioPharma Ltd. -8.18 Million USD -249.633%
Chromocell Therapeutics Corporation -6.86 Million USD -316.771%
CEL-SCI Corporation -27.56 Million USD -3.772%
iBio, Inc. -14.02 Million USD -103.98%
Lineage Cell Therapeutics, Inc. -24.73 Million USD -15.635%
MAIA Biotechnology, Inc. -20.18 Million USD -41.708%
Matinas BioPharma Holdings, Inc. -22.82 Million USD -25.301%
Navidea Biopharmaceuticals, Inc. -13.87 Million USD -106.125%
NovaBay Pharmaceuticals, Inc. -4.8 Million USD -495.833%
NanoViricides, Inc. -7.75 Million USD -268.695%
Oragenics, Inc. -20.87 Million USD -36.99%
BiomX Inc. -22.81 Million USD -25.356%
BiomX Inc. -22.81 Million USD -25.356%
Protalix BioTherapeutics, Inc. 11.65 Million USD 345.472%
Palatin Technologies, Inc. -29.03 Million USD 1.485%
Scorpius Holdings, Inc. -35.08 Million USD 18.478%